Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12674227rdf:typepubmed:Citationlld:pubmed
pubmed-article:12674227lifeskim:mentionsumls-concept:C0178784lld:lifeskim
pubmed-article:12674227lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:12674227lifeskim:mentionsumls-concept:C1441506lld:lifeskim
pubmed-article:12674227lifeskim:mentionsumls-concept:C1512693lld:lifeskim
pubmed-article:12674227pubmed:issue3lld:pubmed
pubmed-article:12674227pubmed:dateCreated2003-4-3lld:pubmed
pubmed-article:12674227pubmed:abstractTextA previously described system for modeling organ deformation using finite element analysis has been extended to permit dose calculation. Using this tool, the calculated dose to the liver during radiotherapy can be compared using a traditional static model (STATIC), a model including rigid body motion (RB), and finally a model that incorporates rigid body motion and deformation (RBD). A model of the liver, consisting of approximately 6000 tetrahedral finite elements distributed throughout the contoured volume, is created from the CT data obtained at exhale. A deformation map is then created to relate the liver in the exhale CT data to the liver in the inhale CT data. Six intermediate phase positions of each element are then calculated from their trajectories. The coordinates of the centroid of each element at each phase are used to determine the dose received. These intermediate dose values are then time weighted according to a population-modeled breathing pattern to determine the total dose to each element during treatment. This method has been tested on four patient datasets. The change in prescribed dose for each patient's actual tumor as well as a simulated tumor of the same size, located in the superior, intermediate, and inferior regions of the liver, was determined using a normal tissue complication model, maintaining a predicted probability of complications of 15%. The average change in prescribed dose from RBD to STATIC for simulated tumors in the superior, intermediate, and inferior regions are 4.0 (range 2.1 to 5.3), -3.6 (range -5.0 to -2.2), and -14.5 (range -27.0 to -10.0) Gy, respectively. The average change in prescribed dose for the patient's actual tumor was -0.4 Gy (range -4.1 to 1.7 Gy). The average change in prescribed dose from RBD to RB for simulated tumors in the superior, intermediate, and inferior regions are -0.04 (range -2.4 to 2.2), 0.2 (range -1.5 to 1.9), and 3.9 (range 0.8 to 7.3) Gy, respectively. The average change in the prescribed dose for the patient's actual tumor was 0.7 Gy (range 0.2 to 1.1 Gy). This patient sampling indicates the potential importance of including deformation in dose calculations.lld:pubmed
pubmed-article:12674227pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12674227pubmed:languageenglld:pubmed
pubmed-article:12674227pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12674227pubmed:citationSubsetIMlld:pubmed
pubmed-article:12674227pubmed:statusMEDLINElld:pubmed
pubmed-article:12674227pubmed:monthMarlld:pubmed
pubmed-article:12674227pubmed:issn0094-2405lld:pubmed
pubmed-article:12674227pubmed:authorpubmed-author:McShanD LDLlld:pubmed
pubmed-article:12674227pubmed:authorpubmed-author:HollisterS...lld:pubmed
pubmed-article:12674227pubmed:authorpubmed-author:Ten HakenR...lld:pubmed
pubmed-article:12674227pubmed:authorpubmed-author:BalterJ MJMlld:pubmed
pubmed-article:12674227pubmed:authorpubmed-author:DawsonL ALAlld:pubmed
pubmed-article:12674227pubmed:authorpubmed-author:BrockK KKKlld:pubmed
pubmed-article:12674227pubmed:issnTypePrintlld:pubmed
pubmed-article:12674227pubmed:volume30lld:pubmed
pubmed-article:12674227pubmed:ownerNLMlld:pubmed
pubmed-article:12674227pubmed:authorsCompleteYlld:pubmed
pubmed-article:12674227pubmed:pagination290-5lld:pubmed
pubmed-article:12674227pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:meshHeadingpubmed-meshheading:12674227...lld:pubmed
pubmed-article:12674227pubmed:year2003lld:pubmed
pubmed-article:12674227pubmed:articleTitleInclusion of organ deformation in dose calculations.lld:pubmed
pubmed-article:12674227pubmed:affiliationDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA. kkbrock@umich.edulld:pubmed
pubmed-article:12674227pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12674227pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12674227pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12674227pubmed:publicationTypeEvaluation Studieslld:pubmed
pubmed-article:12674227pubmed:publicationTypeValidation Studieslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12674227lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12674227lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12674227lld:pubmed